Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-01-07
DOI
https://doi.org/10.3389/fimmu.2025.1659650
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis

Jinxiang Yan, Guangwei Yan, Huanhuan Zhang, Xianxu Zeng
Frontiers in Immunology
PARP inhibition in cancer therapy
article

Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis

Jinxiang Yan, Guangwei Yan, Huanhuan Zhang, Xianxu Zeng
article en

Abstract

No abstract available for this paper.
Frontiers in ImmunologyVol. 16
Zhengzhou University (CN), Third Affiliated Hospital of Zhengzhou University (CN)
Good health and well-being
Openalex Percentile: Top 96%
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis — Jinxiang Yan, Guangwei Yan, et al. · Frontiers in Immunology (2026) | TGRS Research Map | TGRS